Home>Topics>Stocks>Vanda Pharmaceuticals

Vanda Pharmaceuticals VNDA

  1. All
  2. Commentary
  3. Headlines
    1. Vanda's Hetlioz Launch Progressing as Expected; Stock More Than Fully Valued

      Commentary

      Thu, 7 Aug 2014

      Vanda Pharmaceuticals ' second-quarter results were generally consistent with our expectations, as the firm reported reasonable progress for its U

    2. Encouraging Early Signs From Vanda's Hetlioz Launch Outweighed by Higher Cost Structure

      Commentary

      Fri, 9 May 2014

      Vanda Pharmaceuticals reported first-quarter results were below our expectations because of significantly higher-than-anticipated operating costs

    3. Raising Vanda's Fair Value Estimate as Confidence in Tasimelteon's Launch Improves

      Commentary

      Tue, 30 Jul 2013

      We're raising our fair value estimate for Vanda VNDA to $10 per share, following the announcement that orphan sleep disorder drug tasimelteon has gained priority review designation

    4. Vanda shares jump as sleep disorder drug moves closer to market

      Headlines

      Tue, 30 Jul 2013

      (Reuters) - Shares of Vanda Pharmaceuticals Inc jumped nearly 42 percent on expectations that its sleep disorder drug could reach market earlier than expected after U.S. health regulators said it...

    5. Vanda Cuts Expenses in 1Q as it Prepares for New Drug Application Submission for Tasimelteon

      Commentary

      Thu, 9 May 2013

      Vanda VNDA reported first-quarter results that matched our expectations for continued stagnant Fanapt growth, countered by lowered operating

    6. Vanda's Fourth Quarter In Line; Focus Remains on Tasi's Midyear Regulatory Submission

      Commentary

      Tue, 12 Feb 2013

      Vanda VNDA reported fourth-quarter results that matched our expectations, and our attention remains focused on the upcoming catalysts for

    7. Vanda to stop developing anti-depressant, shares slip

      Headlines

      Thu, 31 Jan 2013

      (Reuters) - Vanda Pharmaceuticals Inc said it would stop developing its experimental drug for major depressive disorder after it failed to meet the main goal of improving symptoms in patients in a...

    8. Tasimelteon Fails in Depression; Vanda's Hopes Now Rely Solely on Non-24 for Growth

      Commentary

      Thu, 31 Jan 2013

      On the heels of a cluster of good news for tasimelteon in a rare body clock disorder, Vanda VNDA reported that its lead pipeline candidate failed to demonstrate efficacy in its second tested indication of depression. In contrast

    9. Vanda's Second Phase III Trial Reinforces Tasimelteon's Efficacy

      Commentary

      Wed, 23 Jan 2013

      Vanda Pharmaceuticals VNDA reported results from its second Phase III study testing tasimelteon in patients with non-24-hour disorder. We believe the

    10. Our Speculative Biotech Pick Vanda Pops on Positive Phase III Tasimelteon Results

      Commentary

      Tue, 18 Dec 2012

      Vanda Pharmaceuticals VNDA announced positive results for lead pipeline candidate tasimelteon for the treatment of non-24-hour disorder, putting the

    « Prev123Next »
    Content Partners